ZIPRASIDONE | ZIPRASIDONE | ATC N05AE04
NERVOUS SYSTEM TREATMENT OF BIPOLAR DISORDER ANTIPSYCHOTIC DOPAMINE D2 (KI = 4.8 NANOMOLAR) AND D3 (KI = 7.2 NANOMOLAR) ANTAGONISTS SEROTONIN 5HT2A (KI = 0.4 NANOMOLAR) 5HT2C (KI = 1.3 NANOMOLAR) 5HT1D (KI = 2 NANOMOLAR) ANTAGONISTS ALPHA 1 ADRENERGIC RECEPTOR (KI = 10 NANOMOLAR) ANTAGONISTS 5HT1A RECEPTOR AGONIST (KI = 3.4 NANOMOLAR) | ORAL INTRAMUSCULAR | Tmax 7 HOUR F 60 PERCENT VD 97.5 LITER (65 KILOGRAM) PPB 99 PERCENT Cl 29.2 LITER / HOUR (65 KILOGRAM) HT 7 HOUR | ALPHA 1 ADRENERGIC RECEPTOR 5-HYDROXYTRYPTAMINE 1A RECEPTOR D(2) DOPAMINE RECEPTOR 5-HYDROXYTRYPTAMINE 2A RECEPTOR 5-HYDROXYTRYPTAMINE 2C RECEPTOR D(3) DOPAMINE RECEPTOR 5-HYDROXYTRYPTAMINE 1D RECEPTOR | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |